OpGen

OpGen Debt/EBITDA

The Total Debt to EBITDA Ratio of OpGen (OPGN) as of Oct 19, 2026 is 0.08. In the previous year, Total Debt to EBITDA Ratio was -0.83 — a change of -109.25% (higher).

Debt/EBITDA

0.08

YoY

-109.25%

Last updated:

Total Debt to EBITDA Ratio of OpGen is 2025 0.08 . Total Debt to EBITDA Ratio of OpGen was 2024 -0.83 . It decreases by -109.25% higher compared to the previous year.

The OpGen Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
-0.09 USD
Jan 1, 2018
-0.14 USD
Jan 1, 2019
-0.39 USD
Jan 1, 2020
-1.06 USD
Jan 1, 2021
-1.08 USD
Jan 1, 2022
-0.67 USD
Jan 1, 2023
-0.83 USD
Jan 1, 2025
0.08 USD
The OpGen Debt/EBITDA history
YEARDebt/EBITDAYoY
0.08-109.25%
-0.83+24.49%
-0.67-38.27%
-1.08+1.78%
-1.06+174.23%
-0.39+169.53%
-0.14+69.11%
-0.09+19.32%
-0.07-36.45%
-0.11-80.74%
-0.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen Inc is a biotechnology company based in Gaithersburg, Maryland, operating within the Health Care sector. The company went public on May 5, 2015, with ticker OPGN and ISIN US68373L5057. It currently employs three people. OpGen develops molecular information solutions focused on combating infectious diseases in global healthcare settings. The company's technology involves DNA tests and bioinformatics to address antibiotic resistance, assisting healthcare providers in managing patient care decisions and monitoring the spread of multidrug-resistant microorganisms. Its solutions aim to guide clinicians with information about life-threatening infections and help manage patient outcomes. The company's website is http://opgen.com/. OpGen is engaged in creating tools to help protect the hospital biome through customized screening and surveillance. The firm markets its high-resolution DNA tests under the Acuitas trade name. The company has a global network of customers and partners. OpGen does not provide specific details on its product names beyond Acuitas, and no additional financial figures or historical data are available in the provided information. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Total Debt to EBITDA Ratio of OpGen is 0.08 in 2025.

Total Debt to EBITDA Ratio of OpGen changed from -0.83 to 0.08, representing a -109.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio OpGen since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's OpGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — OpGen

All Key Metrics — OpGen